Characterizing DNA methylation patterns in pancreatic cancer genome

Molecular Oncology

Volumn 3, Issue 5-6, 2009, Pages 425-438

  Tan, Aik Choon ^a   Jimeno, Antonio ^a   Lin, Steven H ^c   Wheelhouse, Jenna ^a   Chan, Fonda ^a   Solomon, Anna ^a   Rajeshkumar, N V ^a   Rubio Viqueira, Belen ^b   Hidalgo, Manuel ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Centro Integral Oncologico Clara Campal   (Spain)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DNA methylation; Gemcitabine; Gene expression; Hypermethylation; Hypomethylation; Pancreatic cancer

Indexed keywords

GEMCITABINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DRUG SENSITIVITY; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREAS TUMOR; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TREATMENT RESPONSE; TUMOR GENE;

EID: 70350574158     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2009.03.004     Document Type: Article

References (38)

1. Bibikova M., Lin Z., Zhou L., Chudin E., Garcia E.W., Wu B., Doucet D., Thomas N.J., Wang Y., Vollmer E., Goldmann T., Seifart C., Jiang W., Barker D.L., Chee M.S., Floros J., and Fan J.B. High-throughput DNA methylation profiling using universal bead arrays. Genome Research 16 (2006) 383-393
2. Chen J., Rocken C., Nitsche B., Hosius C., Gschaidmeier H., Kahl S., Malfertheiner P., and Ebert M.P.A. The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression. Cancer Letters 233 (2006) 328-337
3. Cui H., Onyango P., Brandenburg S., Wu Y., Hsieh C.L., and Feinberg A.P. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Research 62 (2002) 6442-6446
4. de Hoon M.J.L., Imoto S., Nolan J., and Miyano S. Open source clustering software. Bioinformatics 20 (2004) 1453-1454
5. De Smet C., Loriot A., and Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5′ region of gene MAGE-A1 in tumor cells. Molecular and Cellular Biology 24 (2004) 4781-4790
6. Ebert M.P.A., Hernberg S., Fei G., Sokolowski A., Schulz H.U., Lippert H., and Malfertheiner P. Induction and expression of cyclin D3 in human pancreatic cancer. Journal of Cancer Research and Clinical Oncology 127 (2001) 449-454
7. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nature Reviews Genetics 8 (2007) 286-298
8. Esteller M., Corn P.G., Baylin S.B., and Herman J.G. A gene hypermethylation profile of human cancer. Cancer Research 61 (2001) 3225-3229
9. Esteller M., Garcia-Foncillas J., Andion E., Goodman S.N., Hidalgo O.F., Vanaclocha V., Baylin S.B., and Herman J.G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. The New England Journal of Medicine 343 (2000) 1350-1354
10. Feinberg A.P., Ohlsson R., and Henikoff S. The epigenetic progenitor origin of human cancer. Nature Reviews Genetics 7 (2006) 21-33
11. Gansauge S., Gansauge F., Ramadani M., Stobbe H., Rau B., Harada N., and Beger H.G. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Research 57 (1997) 1634-1637
12. Golub T.R., Slonim D.K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J.P., Coller H., Loh M.L., Downing J.R., Caligiuri M.A., Bloomfield C.D., and Lander E.S. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286 (1999) 531-537
13. Han H., Bearss D.J., Browne L.W., Calaluce R., Nagle R.B., and Von Hoff D.D. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Research 62 (2002) 2890-2896
14. Herman J.G., and Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. The New England Journal of Medicine 349 (2003) 2042-2054
15. Iacobuzio-Donahue C.A., Maitra A., Olsen M., Lowe A.W., Van Heek N.T., Rosty C., Walter K., Sato N., Parker A., Ashfaq R., Jaffee E., Ryu B., Jones J., Eshleman J.R., Yeo C.J., Cameron J.L., Kern S.E., Hruban R.H., Brown P.O., and Goggins M. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. American Journal of Pathology 162 (2003) 1151-1162
16. Iacobuzio-Donahue C.A., Maitra A., Shen-Ong G.L., van Heek T., Ashfaq R., Meyer R., Walter K., Berg K., Hollingsworth M.A., Cameron J.L., Yeo C.J., Kern S.E., Goggins M., and Hruban R.H. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. American Journal of Pathology 160 (2002) 1239-1249
17. Jacquemin P., Lannoy V.J., Rousseau G.G., and Lemaigre F.P. OC-2, a novel mammalian member of the ONECUT class of homeodomain transcription factors whose function in liver partially overlaps with that of hepatocyte nuclear factor-6. Journal of Biological Chemistry 274 (1999) 2665-2671
18. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA: A Cancer Journal for Clinicians 57 (2007) 43-66
19. Jimeno A., and Hidalgo M. Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Molecular Cancer Therapeutics 5 (2006) 787-796
20. Jones P.A., and Baylin S.B. The fundamental role of epigenetic events in cancer. Nature Reviews Genetics 3 (2002) 415-428
21. Kuhlmann K.F.D., van Till J.W.O., Boermeester M.A., de Reuver P.R., Tzvetanova I.D., Offerhaus G.J.A., ten Kate F.J.W., Busch O.R.C., van Gulik T.M., Gouma D.J., and Crawford H.C. Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer. Cancer Epidemiology, Biomarkers & Prevention 16 (2007) 886-891
22. Laird P.W. The power and the promise of DNA methylation markers. Nature Reviews Cancer 3 (2003) 253-266
23. Logsdon C.D., Simeone D.M., Binkley C., Arumugam T., Greenson J.K., Giordano T.J., Misek D.E., and Hanash S. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Research 63 (2003) 2649-2657
24. Lowe A.W., Olsen M., Hao Y., Lee S.P., Taek Lee K., Chen X., van de Rijn M., and Brown P.O. Gene expression patterns in pancreatic tumors, cells and tissues. PLoS ONE 2 (2007) e323
25. Matsubayashi H., Sato N., Fukushima N., Yeo C.J., Walter K.M., Brune K., Sahin F., Hruban R.H., and Goggins M. Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. Clinical Cancer Research 9 (2003) 1446-1452
26. Rosenbaum E., Hoque M.O., Cohen Y., Zahurak M., Eisenberger M.A., Epstein J.I., Partin A.W., and Sidransky D. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clinical Cancer Research 11 (2005) 8321-8325
27. Rubio-Viqueira B., Jimeno A., Cusatis G., Zhang X., Iacobuzio-Donahue C., Karikari C., Shi C., Danenberg K., Danenberg P.V., Kuramochi H., Tanaka K., Singh S., Salimi-Moosavi H., Bouraoud N., Amador M.L., Altiok S., Kulesza P., Yeo C., Messersmith W., Eshleman J., Hruban R.H., Maitra A., and Hidalgo M. An in vivo platform for translational drug development in pancreatic cancer. Clinical Cancer Research 12 (2006) 4652-4661
28. Ryu B., Jones J., Blades N.J., Parmigiani G., Hollingsworth M.A., Hruban R.H., and Kern S.E. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Research 62 (2002) 819-826
29. Saldanha A.J. Java Treeview - extensible visualization of microarray data. Bioinformatics 20 (2004) 3246-3248
30. Sato N., Maitra A., Fukushima N., van Heek N.T., Matsubayashi H., Iacobuzio-Donahue C.A., Rosty C., and Goggins M. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Research 63 (2003) 4158-4166
31. Satoh A., Toyota M., Itoh F., Sasaki Y., Suzuki H., Ogi K., Kikuchi T., Mita H., Yamashita T., Kojima T., Kusano M., Fujita M., Hosokawa M., Endo T., Tokino T., and Imai K. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Research 63 (2003) 8606-8613
32. Satoh Y., Nakagawachi T., Nakadate H., Kaneko Y., Masaki Z., Mukai T., and Soejima H. Significant reduction of WT1 gene expression, possibly due to epigenetic alteration in Wilms' tumor. The Journal of Biochemistry 133 (2003) 303-308
33. Scholz C., Nimmrich I., Burger M., Becker E., Dörken B., Ludwig W.D., and Maier S. Distinction of acute lymphoblastic leukemia from acute myeloid leukemia through microarray-based DNA methylation analysis. Annals of Hematology 84 (2005) 236-244
34. Shen L., Kondo Y., Ahmed S., Boumber Y., Konishi K., Guo Y., Chen X., Vilaythong J.N., and Issa J.P.J. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. Cancer Research 67 (2007) 11335-11343
35. Tusher V.G., Tibshirani R., and Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proceedings of the National Academy of Sciences of the United States of America 98 (2001) 5116-5121
36. Wood L.D., Calhoun E.S., Silliman N., Ptak J., Szabo S., Powell S.M., Riggins G.J., Wang T.L., Yan H., Gazdar A., Kern S.E., Pennacchio L., Kinzler K.W., Vogelstein B., and Velculescu V.E. Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers. Human Mutation 27 (2006) 1060-1061
37. Yang P., Ebbert J.O., Sun Z., and Weinshilboum R.M. Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. Journal of Clinical Oncology 24 (2006) 1761-1769
38. Yegnasubramanian S., Kowalski J., Gonzalgo M.L., Zahurak M., Piantadosi S., Walsh P.C., Bova G.S., De Marzo A.M., Isaacs W.B., and Nelson W.G. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Research 64 (2004) 1975-1986